Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials
The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a prot...
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2024-07, Vol.42 (4), p.e3290-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 4 |
| container_start_page | e3290 |
| container_title | Hematological oncology |
| container_volume | 42 |
| creator | Martino, Enrica Antonia Palmieri, Salvatore Galli, Monica Derudas, Daniele Mina, Roberto Della Pepa, Roberta Zambello, Renato Vigna, Ernesto Bruzzese, Antonella Mangiacavalli, Silvia Zamagni, Elena Califano, Catello Musso, Maurizio Conticello, Concetta Cerchione, Claudio Mele, Giuseppe Di Renzo, Nicola Offidani, Massimo Tarantini, Giuseppe Casaluci, Gloria Margiotta Rago, Angela Ria, Roberto Uccello, Giuseppina Barilà, Gregorio Palumbo, Gaetano Pettine, Loredana Vincelli, Iolanda Donatella Brunori, Marino Accardi, Fabrizio Amico, Valeria Amendola, Angela Fontana, Raffaele Bongarzoni, Velia Rossini, Bernardo Cotzia, Emilia Gozzetti, Alessandro Rizzi, Rita Sgherza, Nicola Reddiconto, Giovanni Maroccia, Antonio Franceschini, Luca Bertuglia, Giuseppe Nappi, Davide Barbieri, Emiliano Gamberi, Barbara Petrucci, Maria Teresa Di Raimondo, Francesco Neri, Antonino Morabito, Fortunato Musto, Pellegrino Gentile, Massimo |
| description | The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab. |
| doi_str_mv | 10.1002/hon.3290 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3063465008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3085227785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2400-9057007f4e3162aef16ca898dcda88f1cd3ee468f18aaec7a5427530d8a91c773</originalsourceid><addsrcrecordid>eNp1kc-KFDEQhxtR3HEVfAIJePFg71bS_9LeZBldYXEvem5qk2omSzppk7Qz48lH8PW8-iRmnFVB8FQp8vFVUb-ieMrhjAOI8413Z5Xo4V6x4tD3JYe2v1-sQHSyBFGJk-JRjLcA-Q_kw-KkkpLLvpOr4vva-rR8WSa8YbNdIpv9hNZoPxlNDJ1mmnY4Udpg9I6YcSyQxTmSPg80BlTJhz2bFpvMbIlNe7LZ8Iqtd4mcJs1Gb63f_vj6bZmZHxkeWUUuUXiZZSn4OJNK5jPlDm0mtz5YzWg3UzDkFLGtSRtWCc4URorMLyke1ss65V0WWJsHKWucUWhZCgZtfFw8GHOhJ3f1tPj4Zv3h4rK8un777uL1ValEDVD20HQA3VhTxVuBNPJWoeylVhqlHLnSFVHd5pdEJNVhU4uuqUBL7Lnquuq0eHH0zsF_WiimYTJRkbXoyC9xqKCt6rYBkBl9_g9665fg8naZko0QXSebv0KVLxPzkYc5mAnDfuAwHOIectzDIe6MPrsTLjcT6T_g73wzUB6BrbG0_69ouLx-_0v4Ew-Uu7M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3085227785</pqid></control><display><type>article</type><title>Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Martino, Enrica Antonia ; Palmieri, Salvatore ; Galli, Monica ; Derudas, Daniele ; Mina, Roberto ; Della Pepa, Roberta ; Zambello, Renato ; Vigna, Ernesto ; Bruzzese, Antonella ; Mangiacavalli, Silvia ; Zamagni, Elena ; Califano, Catello ; Musso, Maurizio ; Conticello, Concetta ; Cerchione, Claudio ; Mele, Giuseppe ; Di Renzo, Nicola ; Offidani, Massimo ; Tarantini, Giuseppe ; Casaluci, Gloria Margiotta ; Rago, Angela ; Ria, Roberto ; Uccello, Giuseppina ; Barilà, Gregorio ; Palumbo, Gaetano ; Pettine, Loredana ; Vincelli, Iolanda Donatella ; Brunori, Marino ; Accardi, Fabrizio ; Amico, Valeria ; Amendola, Angela ; Fontana, Raffaele ; Bongarzoni, Velia ; Rossini, Bernardo ; Cotzia, Emilia ; Gozzetti, Alessandro ; Rizzi, Rita ; Sgherza, Nicola ; Reddiconto, Giovanni ; Maroccia, Antonio ; Franceschini, Luca ; Bertuglia, Giuseppe ; Nappi, Davide ; Barbieri, Emiliano ; Gamberi, Barbara ; Petrucci, Maria Teresa ; Di Raimondo, Francesco ; Neri, Antonino ; Morabito, Fortunato ; Musto, Pellegrino ; Gentile, Massimo</creator><creatorcontrib>Martino, Enrica Antonia ; Palmieri, Salvatore ; Galli, Monica ; Derudas, Daniele ; Mina, Roberto ; Della Pepa, Roberta ; Zambello, Renato ; Vigna, Ernesto ; Bruzzese, Antonella ; Mangiacavalli, Silvia ; Zamagni, Elena ; Califano, Catello ; Musso, Maurizio ; Conticello, Concetta ; Cerchione, Claudio ; Mele, Giuseppe ; Di Renzo, Nicola ; Offidani, Massimo ; Tarantini, Giuseppe ; Casaluci, Gloria Margiotta ; Rago, Angela ; Ria, Roberto ; Uccello, Giuseppina ; Barilà, Gregorio ; Palumbo, Gaetano ; Pettine, Loredana ; Vincelli, Iolanda Donatella ; Brunori, Marino ; Accardi, Fabrizio ; Amico, Valeria ; Amendola, Angela ; Fontana, Raffaele ; Bongarzoni, Velia ; Rossini, Bernardo ; Cotzia, Emilia ; Gozzetti, Alessandro ; Rizzi, Rita ; Sgherza, Nicola ; Reddiconto, Giovanni ; Maroccia, Antonio ; Franceschini, Luca ; Bertuglia, Giuseppe ; Nappi, Davide ; Barbieri, Emiliano ; Gamberi, Barbara ; Petrucci, Maria Teresa ; Di Raimondo, Francesco ; Neri, Antonino ; Morabito, Fortunato ; Musto, Pellegrino ; Gentile, Massimo</creatorcontrib><description>The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.</description><identifier>ISSN: 0278-0232</identifier><identifier>ISSN: 1099-1069</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3290</identifier><identifier>PMID: 38818978</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anemia ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Clinical trials ; Dexamethasone ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Dexamethasone - therapeutic use ; Drug Resistance, Neoplasm ; elotuzumab ; Fatalities ; Female ; Follow-Up Studies ; Humans ; Immunotherapy ; Lymphopenia ; Male ; Middle Aged ; Monoclonal antibodies ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Multiple Myeloma - pathology ; Multivariate analysis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Neutropenia ; pomalidomide ; Proteasome inhibitors ; Proteasomes ; Retrospective Studies ; salvage therapy ; Survival ; Survival Rate ; Targeted cancer therapy ; Thalidomide - administration & dosage ; Thalidomide - adverse effects ; Thalidomide - analogs & derivatives ; Thalidomide - therapeutic use ; Thrombocytopenia</subject><ispartof>Hematological oncology, 2024-07, Vol.42 (4), p.e3290-n/a</ispartof><rights>2024 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2400-9057007f4e3162aef16ca898dcda88f1cd3ee468f18aaec7a5427530d8a91c773</cites><orcidid>0000-0001-5641-231X ; 0000-0001-8635-6902 ; 0000-0001-9553-2082 ; 0000-0003-4813-8618 ; 0000-0002-9456-2404 ; 0009-0009-3785-9824 ; 0000-0003-3148-6608 ; 0000-0003-2749-7347 ; 0000-0002-1515-0090 ; 0000-0002-7736-2822 ; 0000-0001-9634-4147 ; 0000-0003-3430-6115 ; 0000-0002-9768-698X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.3290$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.3290$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38818978$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martino, Enrica Antonia</creatorcontrib><creatorcontrib>Palmieri, Salvatore</creatorcontrib><creatorcontrib>Galli, Monica</creatorcontrib><creatorcontrib>Derudas, Daniele</creatorcontrib><creatorcontrib>Mina, Roberto</creatorcontrib><creatorcontrib>Della Pepa, Roberta</creatorcontrib><creatorcontrib>Zambello, Renato</creatorcontrib><creatorcontrib>Vigna, Ernesto</creatorcontrib><creatorcontrib>Bruzzese, Antonella</creatorcontrib><creatorcontrib>Mangiacavalli, Silvia</creatorcontrib><creatorcontrib>Zamagni, Elena</creatorcontrib><creatorcontrib>Califano, Catello</creatorcontrib><creatorcontrib>Musso, Maurizio</creatorcontrib><creatorcontrib>Conticello, Concetta</creatorcontrib><creatorcontrib>Cerchione, Claudio</creatorcontrib><creatorcontrib>Mele, Giuseppe</creatorcontrib><creatorcontrib>Di Renzo, Nicola</creatorcontrib><creatorcontrib>Offidani, Massimo</creatorcontrib><creatorcontrib>Tarantini, Giuseppe</creatorcontrib><creatorcontrib>Casaluci, Gloria Margiotta</creatorcontrib><creatorcontrib>Rago, Angela</creatorcontrib><creatorcontrib>Ria, Roberto</creatorcontrib><creatorcontrib>Uccello, Giuseppina</creatorcontrib><creatorcontrib>Barilà, Gregorio</creatorcontrib><creatorcontrib>Palumbo, Gaetano</creatorcontrib><creatorcontrib>Pettine, Loredana</creatorcontrib><creatorcontrib>Vincelli, Iolanda Donatella</creatorcontrib><creatorcontrib>Brunori, Marino</creatorcontrib><creatorcontrib>Accardi, Fabrizio</creatorcontrib><creatorcontrib>Amico, Valeria</creatorcontrib><creatorcontrib>Amendola, Angela</creatorcontrib><creatorcontrib>Fontana, Raffaele</creatorcontrib><creatorcontrib>Bongarzoni, Velia</creatorcontrib><creatorcontrib>Rossini, Bernardo</creatorcontrib><creatorcontrib>Cotzia, Emilia</creatorcontrib><creatorcontrib>Gozzetti, Alessandro</creatorcontrib><creatorcontrib>Rizzi, Rita</creatorcontrib><creatorcontrib>Sgherza, Nicola</creatorcontrib><creatorcontrib>Reddiconto, Giovanni</creatorcontrib><creatorcontrib>Maroccia, Antonio</creatorcontrib><creatorcontrib>Franceschini, Luca</creatorcontrib><creatorcontrib>Bertuglia, Giuseppe</creatorcontrib><creatorcontrib>Nappi, Davide</creatorcontrib><creatorcontrib>Barbieri, Emiliano</creatorcontrib><creatorcontrib>Gamberi, Barbara</creatorcontrib><creatorcontrib>Petrucci, Maria Teresa</creatorcontrib><creatorcontrib>Di Raimondo, Francesco</creatorcontrib><creatorcontrib>Neri, Antonino</creatorcontrib><creatorcontrib>Morabito, Fortunato</creatorcontrib><creatorcontrib>Musto, Pellegrino</creatorcontrib><creatorcontrib>Gentile, Massimo</creatorcontrib><title>Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><description>The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anemia</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Clinical trials</subject><subject>Dexamethasone</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - adverse effects</subject><subject>Dexamethasone - therapeutic use</subject><subject>Drug Resistance, Neoplasm</subject><subject>elotuzumab</subject><subject>Fatalities</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lymphopenia</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - mortality</subject><subject>Multiple Myeloma - pathology</subject><subject>Multivariate analysis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neutropenia</subject><subject>pomalidomide</subject><subject>Proteasome inhibitors</subject><subject>Proteasomes</subject><subject>Retrospective Studies</subject><subject>salvage therapy</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Targeted cancer therapy</subject><subject>Thalidomide - administration & dosage</subject><subject>Thalidomide - adverse effects</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - therapeutic use</subject><subject>Thrombocytopenia</subject><issn>0278-0232</issn><issn>1099-1069</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc-KFDEQhxtR3HEVfAIJePFg71bS_9LeZBldYXEvem5qk2omSzppk7Qz48lH8PW8-iRmnFVB8FQp8vFVUb-ieMrhjAOI8413Z5Xo4V6x4tD3JYe2v1-sQHSyBFGJk-JRjLcA-Q_kw-KkkpLLvpOr4vva-rR8WSa8YbNdIpv9hNZoPxlNDJ1mmnY4Udpg9I6YcSyQxTmSPg80BlTJhz2bFpvMbIlNe7LZ8Iqtd4mcJs1Gb63f_vj6bZmZHxkeWUUuUXiZZSn4OJNK5jPlDm0mtz5YzWg3UzDkFLGtSRtWCc4URorMLyke1ss65V0WWJsHKWucUWhZCgZtfFw8GHOhJ3f1tPj4Zv3h4rK8un777uL1ValEDVD20HQA3VhTxVuBNPJWoeylVhqlHLnSFVHd5pdEJNVhU4uuqUBL7Lnquuq0eHH0zsF_WiimYTJRkbXoyC9xqKCt6rYBkBl9_g9665fg8naZko0QXSebv0KVLxPzkYc5mAnDfuAwHOIectzDIe6MPrsTLjcT6T_g73wzUB6BrbG0_69ouLx-_0v4Ew-Uu7M</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Martino, Enrica Antonia</creator><creator>Palmieri, Salvatore</creator><creator>Galli, Monica</creator><creator>Derudas, Daniele</creator><creator>Mina, Roberto</creator><creator>Della Pepa, Roberta</creator><creator>Zambello, Renato</creator><creator>Vigna, Ernesto</creator><creator>Bruzzese, Antonella</creator><creator>Mangiacavalli, Silvia</creator><creator>Zamagni, Elena</creator><creator>Califano, Catello</creator><creator>Musso, Maurizio</creator><creator>Conticello, Concetta</creator><creator>Cerchione, Claudio</creator><creator>Mele, Giuseppe</creator><creator>Di Renzo, Nicola</creator><creator>Offidani, Massimo</creator><creator>Tarantini, Giuseppe</creator><creator>Casaluci, Gloria Margiotta</creator><creator>Rago, Angela</creator><creator>Ria, Roberto</creator><creator>Uccello, Giuseppina</creator><creator>Barilà, Gregorio</creator><creator>Palumbo, Gaetano</creator><creator>Pettine, Loredana</creator><creator>Vincelli, Iolanda Donatella</creator><creator>Brunori, Marino</creator><creator>Accardi, Fabrizio</creator><creator>Amico, Valeria</creator><creator>Amendola, Angela</creator><creator>Fontana, Raffaele</creator><creator>Bongarzoni, Velia</creator><creator>Rossini, Bernardo</creator><creator>Cotzia, Emilia</creator><creator>Gozzetti, Alessandro</creator><creator>Rizzi, Rita</creator><creator>Sgherza, Nicola</creator><creator>Reddiconto, Giovanni</creator><creator>Maroccia, Antonio</creator><creator>Franceschini, Luca</creator><creator>Bertuglia, Giuseppe</creator><creator>Nappi, Davide</creator><creator>Barbieri, Emiliano</creator><creator>Gamberi, Barbara</creator><creator>Petrucci, Maria Teresa</creator><creator>Di Raimondo, Francesco</creator><creator>Neri, Antonino</creator><creator>Morabito, Fortunato</creator><creator>Musto, Pellegrino</creator><creator>Gentile, Massimo</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5641-231X</orcidid><orcidid>https://orcid.org/0000-0001-8635-6902</orcidid><orcidid>https://orcid.org/0000-0001-9553-2082</orcidid><orcidid>https://orcid.org/0000-0003-4813-8618</orcidid><orcidid>https://orcid.org/0000-0002-9456-2404</orcidid><orcidid>https://orcid.org/0009-0009-3785-9824</orcidid><orcidid>https://orcid.org/0000-0003-3148-6608</orcidid><orcidid>https://orcid.org/0000-0003-2749-7347</orcidid><orcidid>https://orcid.org/0000-0002-1515-0090</orcidid><orcidid>https://orcid.org/0000-0002-7736-2822</orcidid><orcidid>https://orcid.org/0000-0001-9634-4147</orcidid><orcidid>https://orcid.org/0000-0003-3430-6115</orcidid><orcidid>https://orcid.org/0000-0002-9768-698X</orcidid></search><sort><creationdate>202407</creationdate><title>Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials</title><author>Martino, Enrica Antonia ; Palmieri, Salvatore ; Galli, Monica ; Derudas, Daniele ; Mina, Roberto ; Della Pepa, Roberta ; Zambello, Renato ; Vigna, Ernesto ; Bruzzese, Antonella ; Mangiacavalli, Silvia ; Zamagni, Elena ; Califano, Catello ; Musso, Maurizio ; Conticello, Concetta ; Cerchione, Claudio ; Mele, Giuseppe ; Di Renzo, Nicola ; Offidani, Massimo ; Tarantini, Giuseppe ; Casaluci, Gloria Margiotta ; Rago, Angela ; Ria, Roberto ; Uccello, Giuseppina ; Barilà, Gregorio ; Palumbo, Gaetano ; Pettine, Loredana ; Vincelli, Iolanda Donatella ; Brunori, Marino ; Accardi, Fabrizio ; Amico, Valeria ; Amendola, Angela ; Fontana, Raffaele ; Bongarzoni, Velia ; Rossini, Bernardo ; Cotzia, Emilia ; Gozzetti, Alessandro ; Rizzi, Rita ; Sgherza, Nicola ; Reddiconto, Giovanni ; Maroccia, Antonio ; Franceschini, Luca ; Bertuglia, Giuseppe ; Nappi, Davide ; Barbieri, Emiliano ; Gamberi, Barbara ; Petrucci, Maria Teresa ; Di Raimondo, Francesco ; Neri, Antonino ; Morabito, Fortunato ; Musto, Pellegrino ; Gentile, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2400-9057007f4e3162aef16ca898dcda88f1cd3ee468f18aaec7a5427530d8a91c773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anemia</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Clinical trials</topic><topic>Dexamethasone</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - adverse effects</topic><topic>Dexamethasone - therapeutic use</topic><topic>Drug Resistance, Neoplasm</topic><topic>elotuzumab</topic><topic>Fatalities</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lymphopenia</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - mortality</topic><topic>Multiple Myeloma - pathology</topic><topic>Multivariate analysis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neutropenia</topic><topic>pomalidomide</topic><topic>Proteasome inhibitors</topic><topic>Proteasomes</topic><topic>Retrospective Studies</topic><topic>salvage therapy</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Targeted cancer therapy</topic><topic>Thalidomide - administration & dosage</topic><topic>Thalidomide - adverse effects</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - therapeutic use</topic><topic>Thrombocytopenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martino, Enrica Antonia</creatorcontrib><creatorcontrib>Palmieri, Salvatore</creatorcontrib><creatorcontrib>Galli, Monica</creatorcontrib><creatorcontrib>Derudas, Daniele</creatorcontrib><creatorcontrib>Mina, Roberto</creatorcontrib><creatorcontrib>Della Pepa, Roberta</creatorcontrib><creatorcontrib>Zambello, Renato</creatorcontrib><creatorcontrib>Vigna, Ernesto</creatorcontrib><creatorcontrib>Bruzzese, Antonella</creatorcontrib><creatorcontrib>Mangiacavalli, Silvia</creatorcontrib><creatorcontrib>Zamagni, Elena</creatorcontrib><creatorcontrib>Califano, Catello</creatorcontrib><creatorcontrib>Musso, Maurizio</creatorcontrib><creatorcontrib>Conticello, Concetta</creatorcontrib><creatorcontrib>Cerchione, Claudio</creatorcontrib><creatorcontrib>Mele, Giuseppe</creatorcontrib><creatorcontrib>Di Renzo, Nicola</creatorcontrib><creatorcontrib>Offidani, Massimo</creatorcontrib><creatorcontrib>Tarantini, Giuseppe</creatorcontrib><creatorcontrib>Casaluci, Gloria Margiotta</creatorcontrib><creatorcontrib>Rago, Angela</creatorcontrib><creatorcontrib>Ria, Roberto</creatorcontrib><creatorcontrib>Uccello, Giuseppina</creatorcontrib><creatorcontrib>Barilà, Gregorio</creatorcontrib><creatorcontrib>Palumbo, Gaetano</creatorcontrib><creatorcontrib>Pettine, Loredana</creatorcontrib><creatorcontrib>Vincelli, Iolanda Donatella</creatorcontrib><creatorcontrib>Brunori, Marino</creatorcontrib><creatorcontrib>Accardi, Fabrizio</creatorcontrib><creatorcontrib>Amico, Valeria</creatorcontrib><creatorcontrib>Amendola, Angela</creatorcontrib><creatorcontrib>Fontana, Raffaele</creatorcontrib><creatorcontrib>Bongarzoni, Velia</creatorcontrib><creatorcontrib>Rossini, Bernardo</creatorcontrib><creatorcontrib>Cotzia, Emilia</creatorcontrib><creatorcontrib>Gozzetti, Alessandro</creatorcontrib><creatorcontrib>Rizzi, Rita</creatorcontrib><creatorcontrib>Sgherza, Nicola</creatorcontrib><creatorcontrib>Reddiconto, Giovanni</creatorcontrib><creatorcontrib>Maroccia, Antonio</creatorcontrib><creatorcontrib>Franceschini, Luca</creatorcontrib><creatorcontrib>Bertuglia, Giuseppe</creatorcontrib><creatorcontrib>Nappi, Davide</creatorcontrib><creatorcontrib>Barbieri, Emiliano</creatorcontrib><creatorcontrib>Gamberi, Barbara</creatorcontrib><creatorcontrib>Petrucci, Maria Teresa</creatorcontrib><creatorcontrib>Di Raimondo, Francesco</creatorcontrib><creatorcontrib>Neri, Antonino</creatorcontrib><creatorcontrib>Morabito, Fortunato</creatorcontrib><creatorcontrib>Musto, Pellegrino</creatorcontrib><creatorcontrib>Gentile, Massimo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martino, Enrica Antonia</au><au>Palmieri, Salvatore</au><au>Galli, Monica</au><au>Derudas, Daniele</au><au>Mina, Roberto</au><au>Della Pepa, Roberta</au><au>Zambello, Renato</au><au>Vigna, Ernesto</au><au>Bruzzese, Antonella</au><au>Mangiacavalli, Silvia</au><au>Zamagni, Elena</au><au>Califano, Catello</au><au>Musso, Maurizio</au><au>Conticello, Concetta</au><au>Cerchione, Claudio</au><au>Mele, Giuseppe</au><au>Di Renzo, Nicola</au><au>Offidani, Massimo</au><au>Tarantini, Giuseppe</au><au>Casaluci, Gloria Margiotta</au><au>Rago, Angela</au><au>Ria, Roberto</au><au>Uccello, Giuseppina</au><au>Barilà, Gregorio</au><au>Palumbo, Gaetano</au><au>Pettine, Loredana</au><au>Vincelli, Iolanda Donatella</au><au>Brunori, Marino</au><au>Accardi, Fabrizio</au><au>Amico, Valeria</au><au>Amendola, Angela</au><au>Fontana, Raffaele</au><au>Bongarzoni, Velia</au><au>Rossini, Bernardo</au><au>Cotzia, Emilia</au><au>Gozzetti, Alessandro</au><au>Rizzi, Rita</au><au>Sgherza, Nicola</au><au>Reddiconto, Giovanni</au><au>Maroccia, Antonio</au><au>Franceschini, Luca</au><au>Bertuglia, Giuseppe</au><au>Nappi, Davide</au><au>Barbieri, Emiliano</au><au>Gamberi, Barbara</au><au>Petrucci, Maria Teresa</au><au>Di Raimondo, Francesco</au><au>Neri, Antonino</au><au>Morabito, Fortunato</au><au>Musto, Pellegrino</au><au>Gentile, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2024-07</date><risdate>2024</risdate><volume>42</volume><issue>4</issue><spage>e3290</spage><epage>n/a</epage><pages>e3290-n/a</pages><issn>0278-0232</issn><issn>1099-1069</issn><eissn>1099-1069</eissn><abstract>The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38818978</pmid><doi>10.1002/hon.3290</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5641-231X</orcidid><orcidid>https://orcid.org/0000-0001-8635-6902</orcidid><orcidid>https://orcid.org/0000-0001-9553-2082</orcidid><orcidid>https://orcid.org/0000-0003-4813-8618</orcidid><orcidid>https://orcid.org/0000-0002-9456-2404</orcidid><orcidid>https://orcid.org/0009-0009-3785-9824</orcidid><orcidid>https://orcid.org/0000-0003-3148-6608</orcidid><orcidid>https://orcid.org/0000-0003-2749-7347</orcidid><orcidid>https://orcid.org/0000-0002-1515-0090</orcidid><orcidid>https://orcid.org/0000-0002-7736-2822</orcidid><orcidid>https://orcid.org/0000-0001-9634-4147</orcidid><orcidid>https://orcid.org/0000-0003-3430-6115</orcidid><orcidid>https://orcid.org/0000-0002-9768-698X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2024-07, Vol.42 (4), p.e3290-n/a |
| issn | 0278-0232 1099-1069 1099-1069 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3063465008 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Anemia Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical trials Dexamethasone Dexamethasone - administration & dosage Dexamethasone - adverse effects Dexamethasone - therapeutic use Drug Resistance, Neoplasm elotuzumab Fatalities Female Follow-Up Studies Humans Immunotherapy Lymphopenia Male Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality Multiple Myeloma - pathology Multivariate analysis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neutropenia pomalidomide Proteasome inhibitors Proteasomes Retrospective Studies salvage therapy Survival Survival Rate Targeted cancer therapy Thalidomide - administration & dosage Thalidomide - adverse effects Thalidomide - analogs & derivatives Thalidomide - therapeutic use Thrombocytopenia |
| title | Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A05%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elotuzumab%20plus%20pomalidomide%20and%20dexamethasone%20in%20relapsed/refractory%20multiple%20myeloma:%20Extended%20follow%E2%80%90up%20of%20a%20multicenter,%20retrospective%20real%E2%80%90world%20experience%20with%20321%20cases%20outside%20of%20controlled%20clinical%20trials&rft.jtitle=Hematological%20oncology&rft.au=Martino,%20Enrica%20Antonia&rft.date=2024-07&rft.volume=42&rft.issue=4&rft.spage=e3290&rft.epage=n/a&rft.pages=e3290-n/a&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3290&rft_dat=%3Cproquest_cross%3E3085227785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3085227785&rft_id=info:pmid/38818978&rfr_iscdi=true |